Glenmark Pharma gets final USFDA nod for migraine drug

Posted on:16 Mar 2016 15:07:18

Glenmark Pharma gets final USFDA nod for migraine drug
16 March 2016 Current Affairs: GlenmarkBSE 1.46 % Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the US market. Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg.the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg." Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016. The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US. Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.


Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs July 2017

21 JULY
NEWS
20 JULY
NEWS
19 JULY
NEWS
18 JULY
NEWS

Current Affairs June 2017

30 JUNE
NEWS
29 JUNE
NEWS
28 JUNE
NEWS
27 JUNE
NEWS

Current Affairs May 2017

31 MAY
NEWS
30 MAY
NEWS
29 MAY
NEWS
27 MAY
NEWS